Vanda Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Vanda Pharmaceuticals

29/07/2025 14:37

Vanda Pharmaceuticals Inc VNDA.OQ VNDA.O is expected to  show a rise in quarterly revenue when it reports  results on July 31 for the period ending June 30 2025

The Washington Washington Dc-based  company is expected to report a 8.2% increase in revenue to $54.597 million from $50.47 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vanda Pharmaceuticals Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $13.00, about 63.8% above its last closing price of $4.70

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.60
-0.60
-0.50
Beat
16.2
Dec. 31 2025
-0.11
-0.11
-0.08
Beat
25
Sep. 30 2024
-0.16
-0.16
-0.09
Beat
44.9​
Jun. 30 2024
-0.21
-0.21
-0.08
Beat
61.9
​​
-0.07
Dec. 31 2023
-0.09
-0.09
-0.04
Beat
55.6​
Sep. 30 2023
-0.04
-0.04
0.00
Beat
100
Jun. 30 2023
-0.13
-0.13
0.03
Beat
123.1

This summary was machine generated July 29 at 13:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)